OBJECTIVES: Horizon scanning is in place in many European countries, as well as outside of the Europe. Slovakia didn´t formalize that approach yet, but extreme pressure on healthcare budget has resulted in the implementation of the pilot project.

METHODS: Rapid scanning was chosen as the most appropriate method for the pilot project. Prioritisation meeting was held at Slovak Medical University. Experts chose the area for scanning, agreed on method and form. Subsequently, all pharmaceutical companies were contacted to report expected new oncological indication registration for already registered molecules or for newly developed molecules. Finally we completed the table report by a literature overview using systematic research from pre-selected sources. The selected period was years 2017-2019.

RESULTS: The report contained 31 molecules in 46 indications. 14 were already registered between 2012 and 2016. 4 new indications are expected the treatment of oncological diseases to molecules that are already registered. 18 new molecules were expected to be registered for the treatment of oncological diseases, 1 of them as the extension of the indication to the molecule, which is expected to be registered in 2017. 4 molecules reported new indications in the period after 2019. 3 already registered molecules were reported without time frame. The return of the questionnaires was 57%. The table was completed by 40 more molecules, 2 of them were excluded due to marketing authorization withdrawal and 15 were excluded due to inappropriate period.

CONCLUSIONS: The report completed by the data from the search created the baseline for next steps – final prioritization based on burden of disease and potential impact on patients and budget impact. This shall result on planning of managed entry processes.